Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
– Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia – SHASTA-3... Read more.
CorVista Health to Present New Data on the Use of Machine Learning as a Non-Invasive Point-of-Care Rule-out Test for Heart Failure at ACC 2024
New data support the feasibility of machine learned algorithms to detect elevated left ventricular end-diastolic pressure (LVEDP) Data collected using the CorVista... Read more.
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
– Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent... Read more.
Angelalign Announces Solid Progress in 2023
SHANGHAI–(BUSINESS WIRE)–On March 19, 2024, Angelalign Technology Inc. (“Angelalign” or the “Company”) announced solid progress in 2023 with... Read more.
egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference
– Study Led by Philippe Généreux, MD, and Colleagues was Presented Today at the 2024 ACC Annual Meeting – – Key Findings Demonstrate Untreated... Read more.
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of... Read more.
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment... Read more.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone... Read more.
Wipro Appoints Srini Pallia as CEO & Managing Director
EAST BRUNSWICK, N.J. & BENGALURU, India–(BUSINESS WIRE)–$WIPRO #CEO–Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology... Read more.
The United States Army and United Football League Announce Exclusive Partnership; U.S. Army Becomes the Presenting Partner of the UFL
WASHINGTON & ARLINGTON, Texas–(BUSINESS WIRE)–The United Football League (“UFL”) today announced an exclusive partnership with The United States... Read more.